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PCV22
AN EVALUATION OF THE CLINICAL AND
ECONOMIC OUTCOMES ASSOCIATED WITH
SWITCHING HYPERLIPIDEMIC PATIENTS TO
PREFERRED STATIN THERAPY IN THE U.S.
DEPARTMENT OF DEFENSE
Omar MA ,Wilson J
University of Texas at Austin, Austin,TX, USA
To contain costs associated with lipid-lowering therapy,
the U.S. Department of Defense awarded a contract for
the statin drugs to the manufacturers of cerivastatin and
simvastatin. Hyperlipidemic patients were supposed to be
converted to the preferred statins on or after October 1,
1999.
OBJECTIVES: The primary goal of this study was to
evaluate the clinical and economic outcomes associated
with switching statin therapy of patients from a non-
preferred statin (atorvastatin, ﬂuvastatin, lovastatin or
pravastatin) to a preferred statin (cerivastatin or 
simvastatin). 
METHODS: The study was conducted using retrospec-
tive data from two groups of patients: those for whom
statin prescription records were available (called “Phar-
macy Group”); and a subset of the patients in the 
Pharmacy Group for whom pre- and post-conversion
lipid proﬁles were available (called “Clinical Group”).
RESULTS: For the 181,787 patients in the Pharmacy
Group, the median decrease between pre- and post-
conversion drug cost per patient per month was $5.35.
This translates into a cost avoidance of $11.7 million per
year. Medication compliance of patients in the Pharmacy
Group remained essentially unchanged from pre-
conversion period (0.95) to post-conversion period
(0.97). Out of the 1,552 patients in the Clinical Group
for whom information on National Cholesterol Educa-
tion Program goal status was available, 56.8 percent were
at goal before the switch and 59.1 percent were at goal
after the switch. LDL cholesterol decreased by 5.1
percent, HDL cholesterol increased by 5.8 percent,
triglycerides increased by 2.1 percent, and total choles-
terol decreased by 0.8 percent. 
CONCLUSION: The statin therapy interchange program
resulted in considerable cost savings to the Department
of Defense without clinically important changes in lipid
proﬁles.
PCV23
THE EFFECT OF b-BLOCKER AND ACE
INHIBITOR THERAPY ON THE RISK OF
HOSPITALIZATION AND RESOURCE
UTILIZATION AMONG PATIENTS WITH CHF
ENROLLED IN A MANAGED CARE
ORGANIZATION
Abarca J, Malone DC,Armstrong EP
University of Arizona,Tucson, AZ, USA
Pharmacotherapy with ACE inhibitors and b-blockers is
now recommended for most CHF patients and offers the
potential to reduce morbidity and mortality associated
with this disease.
OBJECTIVE: The purpose of this study was to evaluate
the effectiveness of b-blocker and ACE inhibitor therapy
on the risk of hospitalization and total direct medical
expenditures among patients with congestive heart failure
enrolled in a managed care organization (MCO). 
METHODS: Retrospective claims data from an MCO
were analyzed for the 1997–1999 period. Subjects were
included if they had an ICD-9-CM code for CHF and
were continuously eligible for 18 months. Subjects were
categorized by whether they were receiving ACE
inhibitor, ACE inhibitor + b-blocker, or neither (‘no-
therapy’). For each group, an index date was deﬁned
based on the initiation of therapy with an ACE inhibitor
or b-blocker and the initial ICD-9-CM CHF claim. The
effect of each therapy on the risk of all-cause hospital-
ization, CHF-related hospitalization, and total direct
medical costs during the subsequent 12 months following
the index date was analyzed using OLS and logistic
regression models.
RESULTS: A total of 1903 eligible patients were
included. The mean (SD) age was 69.4 ± 12.4 years,
48.8% were male, and the mean (SD) chronic disease
score was 5.89 ± 3.78. ACE inhibitor therapy, but not 
b-blocker therapy, were associated with a signiﬁcant
decrease (34.7 percent, p < 0.0001) in the risk of all-cause
hospitalization. Neither therapy was associated with a
statistically signiﬁcant effect on the risk of CHF-related
hospitalization. ACE inhibitor and b-blocker therapies
was associated with $2064 and $1185 lower total direct
medical costs compared to the ‘no-therapy’ cohort (p <
0.001 for both).
CONCLUSIONS: These results are similar to those of
randomized trials demonstrating the beneﬁts of ACE
inhibitor. The ﬁndings for b-blocker therapies were
mixed, potentially due to confounding by indication.
PCV24
APPLICATION OF THE COST OF OBESITY
MODEL FOR COST BENEFIT ANALYSIS (CBA)
OF SIBUTRAMINE AND ORLISTAT:A THIRD
PARTY PAYER’S PERSPECTIVE
Sankaranarayanan J,Viswanathan HN, Bharmal M, Shah B,
Murawski MM
Purdue University, West Lafayette, IN, USA
Sibutramine and orlistat are effective in obesity (a major
independent risk factor for several diseases). High obesity
prevalence, questionable long-term beneﬁts, and drug
costs create a dilemma for insurers on these drug-
coverage decisions.
OBJECTIVE: To determine whether sibutramine or 
orlistat is cost-beneﬁcial in obesity treatment. 
METHODS: Randomized placebo-controlled trials 
evaluating sibutramine or orlistat for weight-loss were
collected from MEDLINE and IPA searches. Inclusion cri-
teria were patients 18 years and older with BMI 27–44
kg/m2. Exclusion criterion was comorbidities. After
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assessing quality, using common endpoints at 6 months,
1, and 2 years, ﬁve trials on orlistat (120mg TID) and six
on sibutramine (10mg QD) were selected. Pooled esti-
mates of weighted mean difference (between placebo and
drug) in proportion of patients losing 10% or more of
body weight (the primary outcome) were derived. Life-
time health and economic beneﬁts of sustained 10%
weight loss for adults aged 35–64 years with mild (BMI 
27.5kg/m2), moderate (BMI 32.5kg/m2) and severe (BMI
37.5kg/m2) obesity from a recently published cost-of-
obesity model (Am J Public Health, 1999,89:1536) of 
the relationship between BMI, risks, and cost of ﬁve
obesity-related diseases (hypertension, hypercholes-
terolemia, diabetes, coronary heart disease, stroke) were
used. Using direct costs, CBA was performed with
weighted average savings (transformed to year 2001 US$)
by age, BMI, and proportion losing 10% or more of body
weight. Sensitivity analysis by varying the proportion of
patients sustaining 10% weight loss (+/-20%) and dis-
count rate was done.
RESULTS: Beneﬁt-cost ratios of orlistat and sibutramine
were less than one for the base-case analysis at 6 months,
1 year and 2 years. Best/worst-case beneﬁt-cost ratio (via
sensitivity analysis) of orlistat remained less than one,
while that of sibutramine was 1.8/1.2 at 1 year.
CONCLUSIONS: Unless the proportion of patients 
sustaining 10% weight-loss increases, neither orlistat nor
sibutramine would prove cost-beneﬁcial in formulary
coverage decisions.
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THE ECONOMIC IMPACTS OF TROUGH: PEAK
RATIO AND LIPOPHILICITY ON COST-
EFFECTIVENESS OF ACE-INHIBITOR THERAPY
FOR HYPERTENSION
Keuffel EL1, Cifaldi M2, Botteman MF3
1HERQuLES, Abt Associates Clinical Trials, Cambridge, MA,
USA; 2Abbott Laboratories, Abbott Park, IL, USA; 3Abt
Associates Clinical Trials, Bethesda, MD, USA
OBJECTIVE: While a “class effect” is often attributed to
ACE-Inhibitor (ACE-I) therapy in hypertension, phar-
macokinetic and pharmacodynamic differences exist
between agents for endpoints such as trough :peak ratio
and lipophilicity. Agents with these clinical advantages
may enable patients to more consistently achieve and
maintain low blood pressure (BP) than agents with lower
trough :peak ratios and poorer lipophilicity. This study
assessed the economic implications of these clinical 
beneﬁts in the management of hypertension. 
METHODS: A literature-based decision model was
developed to project the relative costs and effectiveness
over one year of four commonly prescribed ACE-Is
(benazepril, lisinopril, ramipril and quinapril) versus
trandolapril from the perspective of a typical managed
care plan (MCO) with 100,000 members, of whom 1,700
were projected to take ACE-Is for hypertension. Therapy
effectiveness was measured as the proportion of patients
achieving BP control. Controlled patients were assumed
to incur substantially lower non-drug costs ($599–
$1,048) than uncontrolled patients ($4,449–$17,751).
Drug costs reﬂected the price and actual dose taken based
on national prescription data. In the most conservative
scenario, all therapies were assumed to result in identical
levels of BP control (59%). In the least conservative sce-
nario, it was assumed that patients taking therapies with
either poorer lipophilicity or lower trough: peak ratios
would be less frequently controlled (38%).
RESULTS: Trandolapril saved between $48,000 to
$235,000 compared to other ACE-Is in the most conser-
vative scenario. In the least conservative scenario, the cost
of therapies with lower BP control increased signiﬁcantly
and exceeded that of trandolapril by $1.8 to $2.0 million.
CONCLUSIONS: In both scenarios, trandolapril saved
costs relative to comparator ACE-I therapies. These
savings were driven by trandolapril’s lower price and 
the clinical beneﬁts anticipated to result from its lower
trough :peak ratio and better lipophilicity. These beneﬁts
include more consistent BP control and reduced need for
multiple dosing.
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FIRST RUSSIAN EXPERIENCE OF ASSESSING
WILLINGNESS TO PAY:AVOIDING AMPUTATION
IN CASE OF CRITICAL LIMB ISCHEMIA
Avxentieva M,Vorobyov P, Derkach E, Gerasimov V
Moscow Medical Academy, Moscow, Russia
This study presents ﬁrst attempt in Russia to assess will-
ingness to pay for medication treatment.
OBJECTIVE: To obtain monetary valuation of beneﬁts
concerned with avoiding amputation in case of critical
limb ischemia in Russia. 
METHODS: 191 physicians and 137 health care man-
agers ﬁlled in the questionnaire about their willingness 
to pay for medication treatment for critical limb ischemia
with prostaglandin E1 if amputation rate decreases to
12% in comparison with 48% in present common prac-
tice. The probability of amputation was extracted from 
a retrospective analysis of the outcomes of managing 105
patients with critical limb ischemia in common practice
and a published follow-up study of 752 patients treated
with prostaglandin E1 at Moscow surgery center. The
respondents had to assess their maximum out-of-pocket
expenses and maximum possible expenses for national
health care system (NHCS). 
RESULTS: 22.8% of respondents could not give a mon-
etary value for the hypothetical situation. Median value
for out-of-pocket expenses was 30,000 roubles (about
1,000 USD$); the range 1,500–435,000 roubles for 
physicians and 15,000 roubles (500 USD); the range of
500–175,000 roubles for health care managers. Accord-
ing to physicians opinion, payment from the NHCS
should be 70 ± 30% of the named sum. Health care man-
agers answered that NHCS should cover about 80 ± 27%
of the expenses.
CONCLUSION: First experience of assessing willingness
to pay showed that health care managers in Russia are
